Crohn’s Disease (CD) Treatment Market

Global Crohn's Disease (CD) Treatment Market Snapshot (2023 To 2033)

The global Crohn's disease treatment market is slated to reach a valuation of USD 11.68 billion by the end of 2023. According to Future Market Insights, the market is projected to rise at a steady 4.3% CAGR until 2033, being valued at USD 17.80 billion.

Over the coming years, market growth is predicted to be fueled by the increasing incidence of ulcerative colitis along with Crohn's disease worldwide.

Over than 1.6 million Americans experience ulcerative colitis or Crohn's disease, and almost 70,000 new instances of IBD are thought to be identified in the USA each year, as reported by the Crohn's & Colitis Foundation of America. Furthermore, over than 80,000 people in Australia have IBD, based on the RAH Research Fund report.

Growth in the market is anticipated to be fueled by the availability of a robust product pipeline and anticipated releases over the forecast period. For instance, phase II clinical studies are now underway for AbbVie's ABBV-154, an anti-TNF GRM ADC that is anticipated to be on sale in the next years.

Comparable to this, Lilly's Mirikizumab is a sizable molecule that may be studied as a therapy for Crohn's disease and is anticipated to be on sale in 2023. Modern treatments concentrate on lowering complication risks, inflammation, and sustained remission.

In addition, hospitals and healthcare organizations collaborate closely with pharmaceutical firms to carry out clinical trials and guarantee patient safety. Such initiatives are anticipated to improve research efforts to provide a cutting-edge Crohn's disease therapy.

Also, a crucial development in the market for treating Crohn's disease is the growth of technology. For instance, the market's top players in the treatment of Crohn's disease are placing a strong emphasis on the use of cutting-edge technologies like artificial intelligence (AI) for drug development and the provision of novel therapies for ulcerative colitis and Crohn's disease.

Leading firms and tech entrepreneurs are working together to achieve technical advances so they may take use of each other's technology and abilities to develop unique procedures and increase their market positions. For instance, in May 2021, the Israeli tech startup CytoReason announced a deal with Ferring Pharmaceuticals to use AI technology to speed up the drug development process and discover new therapies for Crohn's disease. Developments as such are expected to boost the global revenues in the market for the treatment of Crohn's disease globally from 2023 to 2033.

Data Points	Key Statistics
Anticipated Base Year Value (2022)	USD 11.2 billion
Expected Market Value (2023)	USD 11.68 billion
Projected Forecast Value (2033)	USD 17.80 billion
Global Growth Rate (2023 to 2033)	4.3% CAGR

2018 To 2022 Crohn's Disease Treatment Market Demand Analysis Vs. Forecast 2023 To 2033

The global Crohn's disease treatment market grew at a CAGR of 3.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.

Any area of the small or large intestine may be affected by Crohn's disease. It may involve many segments, or it could be continuous. Some individuals only have the illness in their colon, which is a section of their big intestine. Thus, these symptoms leads on to more of inflammatory bowel diseases and ultimately leads to Crohn’s disease.

Moreover, market expansion is anticipated to be supported by the rise in the use of initiatives including product launches, innovation, expansions, and partnerships. For instance, RINVOQ, a Janus kinase inhibitor, was approved by the USA FDA in March 2022 for the treatment of Crohn's disease.

Moreover, AbbVie, Inc. declared the completion of its purchase of Allergan in May 2020, which is anticipated to increase the company's product line for the treatment of Crohn's disease. Moreover, throughout the course of the projected period, market expansion is predicted to be supported by the growing use of innovative products and big molecules. As a result, the global Crohn's Disease Treatment Market is expected to forecast a CAGR of over 4% from 2023 to 2033.

Prominent Growth Drivers Influencing Crohn's Disease Treatment Market

Increasing adoption of biologics have been accelerating the demand

Biological therapy such as anti-interleukin & integrin antibodies and anti-tumor necrosis factor (TNF) are frequently utilised for many inflammatory disorders such as Crohn's disease (CD). For treating individuals who cannot be well managed by steroids or aminosalicylates, they are typically regarded as sufficient.

Nevertheless, some individuals may stop responding to these treatments, especially anti-TNFs. There is a desire for treatments with novel MOAs which are less immunogenic than currently available options, and several new classes of medicines are hoping to hit the market within the next few years. Stelara (ustekinumab) is the last biologic licensed for Crohn's disease.

Due to their improved clinical profiles and practical patient dosage, biologics including anti-integrin as well as interleukin inhibitors are gaining ground in the Crohn's Disease market. Hence, the market for Crohn's disease treatment is anticipated to grow throughout the course of the projected period as a result of these developments.

Rising incidence of Inflammatory Bowel Diseases is driving growth

The market under study has shown significant expansion, which may be attributed to the rising incidence of Crohn's disease and inflammatory bowel illnesses globally. According to projections, there will be 18,30,734 people with Crohn's disease in the 8MM in 2021. Between 2023 and 2033, this number is anticipated to increase to 21,91,544.

As per an article published in 2021 by Journal BMC Gastroenterology, there will be an expected rise of 2.5 fold rise in IBD cases in Iran, and 2.3 fold rise in North America by 2035. Such factors are expected to boost the demand for various therapies and treatments for the diagnosis of Crohn’s disease.

What Could Possibly Hinder Crohn's Disease Treatment Market Demand?

Lack of reimbursement policies and high cost are expected to hinder the growth

There is lack of awareness among the various patients suffering from Crohn’s disease in various countries across the globe. Additionally, the higher cost for this kind of treatment, including the drug as well as other cost is expected to restrain the growth of the Crohn’s disease treatment market.

Furthermore, in developing countries like India, Russia and China, there is a scarcity of reimbursement policies for Crohn’s disease treatment, restraining the adoption of the drugs in these regions. The aforementioned issues thus restrict the growth of the Crohn's Disease Treatment Market.

Region-wise Analysis

What Is the Outlook of the North American Crohn's Disease Treatment Market?

Presence of key players and increasing initiatives are accelerating the growth

During the forecast period, the North American market for Crohn's disease treatment is expected to be the most volatile one. As per Future Market Insights, this region is expected to proliferate at a CAGR of 4.9% from 2023 to 2033.

Due to the existence of several powerful market participants and the numerous strategic efforts they have made in the area, they have achieved this dominance. Regional development is additionally made possible by the rising prescription of innovative treatments, improved payment practises, and high treatment rates in the area. The continued development of innovative treatments and supporting governmental policies are also expected to fuel the region's growth. One of the major organizations that supports numerous clinical and translational studies to identify treatments for colitis and Crohn's disease, for instance, is the Crohn's & Colitis Foundation.

Hence, during the forecast period, the North American region can be expected to show a significant growth rate, acquiring a global market share of 42% in the year 2023.

What Can Be Expected from The Asia Pacific Market for Crohn's Disease Treatment?

Enhanced healthcare facilities and strong patient pool to accelerate the growth

During the forecast period, the Asia Pacific market for Crohn's disease treatment is expected to garner a CAGR of 3.6%. Some of the key reasons driving market expansion in the next years include an ageing population, a high chance of acquiring inflammatory illnesses, an increase in the incidence of inflammatory bowel disorders, Crohn's disease, and better healthcare policies in the area.

Also, increased investments by top players in the area and the increasing acceptance of biosimilar and biologics are anticipated to fuel market expansion in the near future. Hence, factors such as these are expected to accelerate the growth in the regional market from 2023 to 2033.

Category-wise Insights

Which drug type segment is expected to gain traction from 2023 to 2033?

The immunomodulators segment will gain the dominant market share

Over the course of the forecast period, the immunomodulators segment by drug type is anticipated to occupy a significant share of the global Crohn's Disease Treatment Market. In 2023, this category is anticipated to dominate with a 53% revenue share.

Due to their superior therapeutic activity, the immunomodulators subgroup of medication types now occupies a leading position in the worldwide Crohn's disease therapy market. The key advantage of these medications is that they lessen the long-term requirement for steroids and stop recurrent flares. Because of this, immunomodulators are occasionally referred to as "steroid-sparing" medications.

They may also be used with other medications, such as biologics, to assist avoid the development of antibodies, which can reduce the effectiveness of biologics. Such factors are expected to accelerate the growth prospects for Crohn's disease treatment from 2023 to 2033.

Which distribution channel segment is expected to gain traction during 2023 to 2033?

The hospital pharmacies segment will demand during the forecast period

According to a report by Future Market Insights, the hospital pharmacy industry would grow within the anticipated time frame. This market sector is expected to hold a 27.3% share of the worldwide market from 2023 to 2033.

Due to the growing number of people visiting hospitals for advice on treatment related to Crohn's disease, the hospital pharmacies sector is anticipated to dominate the worldwide Crohn's disease treatment market.

For instance, up to 80% of those suffering from Crohn's required hospitalization at a certain point in 2020, according to an article posted by WebMD LLC, a web publisher of data pertaining to human health and well-being. As a result, these individuals are expected to only buy medications from hospital pharmacies.

Start-up Scenario

The start-ups in this sector aim to use a number of techniques, such as the launch of new products and acquisitions, to improve their market positions internationally.

• In order to treat patients with Crohn's disease and ulcerative colitis, Gusto Global, a microbiome discovery platform firm dedicated to restoring a healthy microbiome, has created unique bacterial consortia. Gusto's bottom-up rational collaborative design methodology, which is assiduously guided by mechanistic modeling and insights from microbiome ecology and disease etiology, is validated by best-in-class preclinical findings for a Living Biotherapeutic Product.
• Using its implanted neuromodulation device, SetPoint Medical is commencing a clinical study to treat Crohn's disease patients. The vagus nerve is stimulated, which is believed to activate the body's inherent anti-inflammatory reflexes and reduce the symptoms of inflammatory illnesses.

How Competitive is the Market for Crohn's Disease Treatment?

New therapies based on the microbiome and utilizing unique pathways are being developed to treat Crohn's disease. Prominent businesses in the sector are creating unique goods, investing heavily in research and development, and engaging in big acquisitions and partnerships.

Some of the prominent players in the global market for Crohn's disease treatment are:

• Abbvie Inc.
• Celgene Corporation
• Genetech
• Johnson & Johnson
• Pfizer Inc.
• Prometheus Laboratories Inc. (Nestle)
• Salix Pharmaceuticals Inc.
• Takeda's Pharmaceutical Ltd
• Janssen Pharmaceuticals
• Biogen
• AstraZeneca

Some of the important developments of the key players of the market are:

• With Enterome S.A., Takeda has reached a global license, co-development, and co-promotion agreement. A lot of companies, including Enterome, 4D Pharma, BiomX, Synlogics, Vedanta Bioscience, and others, are concentrating on microbiome-based therapies to cure illness. For their product portfolio to be strengthened, these players use both organic and inorganic expansion techniques.
• For the treatment of moderate-to-severe Crohn's disease, a number of biologics have already approved, including the Remicade (infliximab), Cimzia (certolizumab pegol), the anti-integrins Entyvio (vedolizumab), anti-TNFs Humira (adalimumab), and Tysabri (Natalizumab), and the interleukin (IL) 12 and (Risankizumab-rzaa). The market for treating Crohn's disease now has five main firms with branded medications approved: Takeda, Johnson & Johnson (J&J), AbbVie, UCB, and Biogen.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 4.3% from 2023 to 2033
Market value in 2023	USD 11.68 billion
Market value in 2033	USD 17.80 billion
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	USD Billion for Value and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Drug type, Distribution Channel, Region
Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa
Key Countries Profiled	United States, Canada, Brazil, Mexico, United Kingdom, Spain, Germany, Italy, France, China, Japan, South Korea, India, Indonesia, Malaysia, Thailand, Australia, New Zealand, South Africa, GCC Countries
Key Companies Profiled	Abbvie Inc.; Celgene Corporation; Genetech; Johnson & Johnson; Pfizer Inc.; Prometheus Laboratories Inc. (Nestle); Salix Pharmaceuticals Inc.; Takeda Pharmaceutical Ltd; Janssen Pharmaceuticals; Biogen; AstraZeneca
Customization & Pricing	Available on Request

Key Segments Covered in the Crohn's Disease Treatment Market Report

By Drug Type:

• Antibiotics
• Amino Salicylates
• Corticosteroids
• Immunomodulators
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Frequently Asked Questions

What is the Current Crohn’s Disease (CD) Treatment Market Size?

As of 2023, the Crohn's Disease treatment market holds a valuation of USD 11.68 billion.

What are the Growth Prospects for Crohn’s Disease (CD) Treatment Market in the Next Decade?

The Crohn's Disease treatment market is projected to attain a value of USD 17.80 billion by 2033, driven by a CAGR of 4.3% between 2023 and 2033.

What are the Emerging Niches in the Crohn’s Disease (CD) Treatment Market?

Novel drug therapies, personalized treatment approaches, and biological interventions are emerging as notable niches in the Crohn's Disease treatment market.

What Country Rules the Crohn’s Disease (CD) Treatment Market?

The United States leads the Crohn's Disease treatment market with a strong pharmaceutical sector and established gastroenterology healthcare network.

What was the Crohn’s Disease (CD) Treatment Market's Past Record like?

With a slow-paced CAGR of 3.2%, the Crohn's Disease treatment market's revenues surpassed USD 11.2 billion in 2022.